Objective: To examine the prevalence of excretion of urinary isoflavonoids in women and determine any relationships with accustomed macronutrient intake. Design: Volunteers in one of two 4-month studies. Study 1 was a randomised crossover study whereby subjects consumed a placebo or isoflavone supplement for 2 months and crossed over. Study 2 was a parallel design in which subjects consumed a placebo for 1 month and an isoflavone supplement for 3 months. Setting: All subjects were free-living, healthy volunteers. Subjects: A total of 25 (study 1, n ¼ 14; study 2, n ¼ 11) premenopausal women were recruited through advertisements. Interventions: Volunteers were supplemented for 2 months (study 1) or 3 months (study 2) with purified isoflavones (86 mg/ day) derived from red clover. Urinary isoflavonoids were measured during the placebo and the second month of isoflavone treatment. Macronutrient intakes were determined from weighed food records. Results: During isoflavone supplementation, the concentration of urinary total isoflavonoids increased by 15-fold (Po0.0001), with 5.4-fold variation between individuals. Multiple linear regression analysis showed that 24% of this variation could be explained by an interaction between dietary fibre and protein (P ¼ 0.047), with a highly significant inverse association between total isoflavonoid concentration and the protein to fibre ratio (r ¼ À0.51, P ¼ 0.009). Conclusions: Supplementation with purified isoflavones results in an increase in urinary isoflavonoid excretion and part of the individual variation in response is associated with an interaction between intakes of protein and dietary fibre. Whether manipulation of these macronutrients could enhance efficacy of isoflavone supplements remains to be determined.
Introduction
Isoflavones are naturally occurring diphenolic compounds found mainly in the legume family of plants, which includes soybeans, lentils, chickpeas, peanuts, beans and clover (Price & Fenwick, 1985) . Isoflavones possess weak oestrogenic and antioestrogenic activities, and may reduce the risk of chronic diseases such as hormone-sensitive cancers and cardiovascular disease (Adlercreutz & Mazur, 1997) .
Two major isoflavones of relevance in human nutrition are daidzein and genistein, which occur in soybeans as glycosidic conjugates, daidzin and genistin, or in red clover as methoxylated precursors, formononetin and biochanin A, respectively. After ingestion, the greater part of isoflavone metabolism occurs in the large intestine due to the activity of the resident bacteria (Xu et al, 1995) . The weakly oestrogenic precursors can be hydrolysed or demethoxylated to form biologically active forms, daidzein and genistein; daidzein can be reduced to dihydrodaidzein, O-desmethylangolensin (O-dma) or the more oestrogenic isoflavan, equol, while genistein can be reduced to dihydrogenistein or degraded to p-ethylphenol, which is biologically inactive Heinonen et al, 1999) . Metabolites are absorbed as aglycones and conveyed to the liver. In the liver, they can be conjugated with glucuronate or sulphate and secreted into bile to undergo enterohepatic recycling (Setchell & Adlercreutz, 1988) or released into the systemic circulation and finally excreted into urine (Xu et al, 1995) .
Individual differences in bioavailability of the parent isoflavones and metabolites could have important consequences for their potential health benefits and recent studies have focused on measuring concentrations of urinary isoflavonoids as a marker of their absorption and bioavailability. A dose-dependent relationship has been reported between intake and mean excretion of isoflavonoids after 9-day treatments with four levels of soy protein (Karr et al, 1997) . However, intervention studies with soy products have reported surprisingly wide, largely unexplained variation in the excretion of isoflavonoids between individuals ingesting the same dose (Kelly et al, 1993; Hutchins et al, 1995; Tew et al, 1996; Lampe et al, 1998; Slavin et al, 1998; Rowland et al, 2000) . The degree of metabolic conversion of the original plant isoflavones could vary according to differences in the population of the intestinal bacteria involved in the hydrolysis, demethoxylation and reduction of isoflavones. The anaerobic bacterium Eubacterium limosum has been identified as being able to convert biochanin A and formononetin to the more oestrogenic isoflavones genistein and daidzein, respectively, by means of its O-demethoxylating activity (Hur & Rafti, 2000) ; in vitro studies have confirmed that faecal bacteria are involved in the conversion of daidzein to equol (Setchell & Adlercreutz, 1988) . However, other bacteria involved in the biotransformations of isoflavones are yet to be identified.
The variation could also arise from differences in dietary macronutrient intake, which in turn could selectively modify the growth of intestinal bacteria involved in isoflavonoid transformations, particularly in the production of equol Rowland et al, 2000) where only 20-36% of subjects can produce and excrete this metabolite (Kelly et al, 1993; Cassidy et al, 1994; Hutchins et al, 1995; Kirkman et al, 1995; Lu et al, 1996; Lampe et al, 1998; Lu & Anderson 1998; Duncan et al, 2000; Rowland et al, 2000) . Macronutrient composition of the diet could affect bacterial activity by changing the intestinal pH, redox potential or transit time, or influencing the availability of substrates for the bacteria to utilise (Cummings & Macfarlane, 1991) .
In this study, we used data from two intervention studies conducted in our laboratory on hormonal effects of isoflavones in premenopausal women to examine the prevalence of excretion of isoflavonoids and the relationship between their excretion and accustomed macronutrient intake. To provide a comprehensive profile of excretion, a total of eight isoflavonoids were measured, including lesser known metabolites such as dihydrodaidzein and dihydrogenistein. Isoflavones were provided in tablet form to minimise disruption to the usual diet. The hypothesis being tested was that differences in dietary macronutrient intake could contribute to the interindividual variation in excretion of the isoflavonoids.
Subjects and methods

Subjects
Participants were 25 healthy, premenopausal women recruited from The University of Sydney by placement of posters on campus and advertisements in the University News. Potential subjects were interviewed over the phone and in person, and they completed a medical history and lifestyle questionnaire. Exclusion criteria were: use of antibiotics within 3 months prior to commencing the study; regular use of medication such as oral contraceptives or steroids, irregular menstrual cycle, history of cancer, or renal, hepatic or gastrointestinal disorders, variable body weight or exercise regimes and regular weekly consumption of isoflavonoid-rich soy foods. The University of Sydney Human Ethics Review Committee approved the study protocol and participants provided written informed consent prior to the commencement of the study.
Study design
In one of two 4 months, randomised, placebo-controlled trials, examining the effects of isoflavones on oestrogen and cholesterol metabolism there were 14 participants from study 1 and 11 participants from study 2, with mean age 29.971.9 (s.e.m.) y, height 166.371.2 cm and weight 60.971.8 kg. Study 1 was a crossover design in which subjects consumed either the isoflavone or placebo supplement for the first two menstrual cycles and then crossed over for the next two cycles. Study 2 was a parallel design in which the isoflavone group consumed the placebo supplement for the first cycle and the isoflavone supplement for the remaining three cycles, while the placebo group consumed the placebo supplement for all four cycles. In study 2, the placebo group subjects were not selected for the current analysis. Subjects were requested to maintain their accustomed dietary intake and exercise patterns during the studies.
The isoflavone supplement was given in tablet form (kindly provided by Promensil, Novogen Ltd, North Ryde, Australia) and subjects consumed two tablets each morning to provide an isoflavone intake of 86 mg/day. The isoflavones were derived from red clover (Trifolium pratense) and each tablet contained 25.7 mg biochanin A, 4.3 mg genistein, 9.3 mg formononetin and 3.7 mg daidzein. The placebo tablets were identical in appearance to the isoflavone tablets and all tablets contained 0.4 mg tocopherol as preservative with 0.2 mg rosemary extract and 0.4 mg rosemary oil for fragrance. Compliance was assessed by counting the number of surplus tablets returned at the end of each month.
Four 24-h urine samples for analysis of isoflavone metabolites were collected over days 5-8 (where day 1 was the first day of menstruation) of cycles 2 and 4 during study 1, and cycles 1, 3 and 4 during study 2. Samples were collected into 2 l plastic containers that contained 1 g of ascorbic acid and kept at 41C until delivery to the laboratory. The total urine volume of each 24-h sample was recorded. Sodium azide (0.1% w/v) was added to aliquots and then the samples were stored at À801C until analysis. During the third week of each menstrual cycle, participants completed a 3-day weighed food record to include one weekend day and two weekdays. Food records were collected during the third week of each menstrual cycle to control for possible variations in intake during the cycle as we had reported previously (Lyons et al, 1989) . Nutrients were analysed using DIET 1 software (version 4.0, Xyris Software Pty Ltd, Highgate Hill QLD, Australia) with the NUTTAB database of Australian foods. Body weight was assessed weekly throughout the study. For the current analysis, urine samples and food records were utilised from the placebo treatment and second month of isoflavone supplementation in both studies 1 and 2.
Analysis of urinary isoflavonoids
An aliquot of each of the 4 days was combined to give a composite sample for each cycle. A 30 ml aliquot of the composite sample was adjusted to pH 4.6 with 70% (v/v) acetic acid and 75 mg of phloretin (Aldrich, USA) was added as internal standard. b-glucuronidase (100 ml, Helix pomatia, Sigma Chemical Co, USA) was added to the urine sample and incubated for 24 h at 371C. Using [ 3 H]estradiol-glucuronate (New England Nuclear Medicine, USA), the extent of deconjugation by b-glucuronidase was estimated to be 9373% (4). Urinary isoflavones were analysed by HPLC as described by Franke et al (1995) with the following modifications. Isoflavones were extracted from urine using a solid-phase C-18 extraction cartridge (Alltech, Baulkham Hills, NSW, Australia) activated with 5 ml of methanol and 5 ml water. A sample of deconjugated urine (10 ml) was loaded onto the column and washed with 5 ml water. Isoflavones were eluted from the cartridge with methanol (3 ml, HPLC grade) and transferred to an HPLC vial for subsequent analysis.
Isoflavonoid analysis was carried out on a LC-10 chromatograph system with an auto sampler and diode-array detector (Shimadzu, Japan). The extract (10 ml) was injected onto a C18 column (id 5 mm, 3.9 Â 150 mm 2 , Nova Pac; Waters, Milford, MA, USA) and run at a constant temperature of 401C using a gradient mobile phase at a flow rate of 0.9 ml per minute as follows: A ¼ methanol, B ¼ water: 30% A in B (v/v) linearly to 38% in 10 min, stable at 38% for 5 min then linearly to 70% A for 5 min, followed by holding at 30% A for 10 min to equilibrate the system between injections. Isoflavones were quantified using commercial standards, genistein, daidzein (Sigma Chemical Co, USA), biochanin A and formononetin (Aldrich, USA); and equol, O-dma, dihydrodaidzein, dihydrogenistein, 6
0 -hydroxy-O-dma and 5 0 -hydroxy-O-dma, synthesised by one of us (GEJ). Standards, dissolved in methanol, were included in each run. The urine samples were analysed in batches of 10 with all samples from one subject in the same run. The mean recovery was 93% with a range of 89-97% for individual isoflavones. The interassay variations for the isoflavones were between 7 and 16% and intra-assay variations were less than 5%, with a detection limit of 5 ng/ml. The total isoflavonoid concentration was corrected for column recovery and expressed as the sum of urinary excretion over 24 h. Gas chromatographymass spectrometry was used to test the purity of the standards and confirm that the observed HPLC peak corresponded to the expected isoflavone standard and did not include other related compound(s) with similar retention time .
Statistical analysis
Isoflavonoid and macronutrient data from studies 1 and 2 were combined as they were not significantly different. Comparisons of urinary isoflavonoid concentrations and macronutrient intake during the placebo period and the second cycle of isoflavone supplementation were carried out using paired t-tests. Pearson's correlation coefficients were used to determine the associations between urinary isoflavonoid concentrations with Bonferonni adjustment for multiple comparisons. Comparisons of macronutrient intakes between subjects who excreted specific isoflavonoid metabolites, such as equol, dihydrodaidzein and dihydrogenistein, and nonexcretors were carried out using unpaired t-tests. For isoflavonoid metabolites that were excreted by all subjects, such as daidzein, genistein, O-dma, biochanin A and formononetin, a stepwise multiple linear regression model was used to examine the relationship between macronutrient intake and isoflavonoid excretion. The stepwise linear regression included protein, fat, carbohydrate and alcohol, expressed as g/day in Model 1 and as %E in Model 2. Statistical analysis was performed using SPSS (version 10, USA) with values expressed as the mean7s.e.m. A level of Po0.05 was considered statistically significant, adjusted for multiple comparisons as required.
Results
Mean body mass indices were not significantly different between placebo and isoflavone supplementation periods (22.170.7 vs 22.270.7 kg/m 2 , respectively). Apparent compliance, as determined by tablet count in returned bottles each month, was similar for both groups (97.870.2 vs 97.970.2% placebo vs isoflavone, respectively). Average daily intakes of energy, macronutrients and dietary fibre determined from 3-day food records were stable during the study and were not significantly different during placebo and isoflavone periods ( Table 1) .
As anticipated, mean total urinary isoflavonoid concentrations increased significantly by 15-fold during the isoflavone compared to placebo supplementation periods ( Table 2) . Individual metabolites were also significantly higher during isoflavone treatment: biochanin A, daidzein and genistein increased six-to 10-fold, formononetin and dihydrodaidzein increased 13-fold and equol increased 27-fold and O-dma increased 228-fold. 6 0 -hydroxy-O-dma and 5 0 -hydroxy-Odma were not detected in any urine samples.
There were significant positive associations between concentrations of daidzein and genistein (r ¼ 0.63, Po0.001), and daidzein and formononetin (r ¼ 0.65, Po0.001). Concentrations of total urinary isoflavonoids were significantly associated with daidzein (r ¼ 0.74, Po0.001) and genistein (r ¼ 0.69, Po0.001). There were no significant associations between other individual metabolites. All subjects excreted detectable quantities of daidzein, formononetin, genistein and biochanin A. The prevalences for excretion of metabolites were: O-dma 96% (24 of 25 subjects), dihydrodaidzein 64% (16 of 25), equol 24% (6 of 25) and dihydrogenistein 12% (three of 25). Mean urinary concentration of daidzein and metabolites was greater than that of genistein and related compounds (54.5721.7 vs 17.4713.4 mmol/day, sum of daidzein, formononetin, dihydrodaidzein, equol and Odma vs sum of genistein, biochanin A and dihydrogenistein, respectively, Po0.0001). The mean recovery of total isoflavonoids as a percentage of the dose was 2279% (range 7-39%) and the mean recoveries of metabolites of daidzein and genistein were 55723 and 7.876.0%, respectively. Subjects who excreted equol or dihydrodaidzein consumed significantly less protein as percentage of energy (Figure 1 ). There were no significant differences between the macronutrient intakes of dihydrogenistein excretors and nonexcretors. Stepwise multiple linear regression analysis showed that total isoflavonoid concentrations were associated with an interaction between intakes of dietary fibre and protein (total isoflavones ¼ 1.80 (fibre g/day)À0.48 (protein g/day) þ 63.7, r 2 ¼ 0.24, P ¼ 0.047). A highly significant inverse association was found between the total isoflavonoid concentrations and the ratios of protein to dietary fibre intake ( Figure 2 ). There were no significant associations between urinary concentrations of daidzein, genistein, O-dma, biochanin A or formononetin and intakes of individual macronutrients expressed as g/day or as a percentage of energy.
Discussion
Following 2 month supplementation with purified isoflavones, mean concentration of urinary isoflavonoids increased by 15-fold compared to baseline (Po0.0001) and a five-fold variation was observed between individuals with concentrations ranging from 24 to 127 mmol/24 h. A significant proportion (24%; P ¼ 0.047) of this variation could be explained by an interaction between intakes of protein and dietary fibre, with a significant inverse association between urinary isoflavonoid concentration and the dietary protein to fibre ratio (r ¼ À0.51, P ¼ 0.009). This association was independent of body weight or body mass index. It did not arise from variation in content of the isoflavone tablets since the dose was confirmed by independent analyses (Setchell et al, 2001; Howes & Howes, 2000) , nor from lack of compliance. Intake of isoflavones from unspecified sources such as soy foods was also minimal since subjects were excluded from participating if they consumed soy foods on a regular basis, and dietary intake, assessed by weighed records, did not change during the intervention period. The current study measured eight urinary isoflavonoids including daidzein, genistein and methoxylated precursors (formononetin and biochanin A), present in the isoflavone supplement, and four isoflavonoid metabolites (equol, Odma, dihydrodaidzein and dihydrogenistein). The mean recovery of total isoflavonoids, expressed as a percentage of supplement dose excreted during 24 h, was 2279%, which is similar to values of 19 and 30% reported in previous studies using supplements derived from red clover (Hodgson et al, 1998; Nestel et al, 1999) . Greater recovery was observed with daidzein and related compounds (55723%) compared to those of genistein (7.876.0%), and is consistent with previous findings with isoflavones derived from soy (Kelly al, 1993; Hutchins et al, 1995; Xu et al, 1995; Lu et al, 1996; Tew et al, 1996) .
All subjects excreted daidzein, genistein, formononetin and biochanin A, although concentrations varied 13-19 fold between individuals. Biochanin A and formononetin are provided in high quantities from the supplement; however, they are also supplied by the diet in small quantities in foods such as sunflower seeds, various beans and peanuts (Mazur et al, 1996 (Mazur et al, , 1998 . Not all subjects excreted the isoflavonoid metabolites and wider variation (20-40 fold) was seen between individuals: most subjects (96%) excreted O-dma but only 24% produce equol and of the lesser known metabolites, dihydrodaidzein was excreted by 64% and dihydrogenistein was detected in 12% of subjects.
Some previous studies have reported a reciprocal relationship between excretion of equol and O-dma (Hutchins et al, 1995; Kelly et al, 1995; Arai et al, 2000) although this was not confirmed in the current study or other studies (Karr et al, 1997; Lampe et al, 1998; Rowland et al, 2000) . Interest is focused on equol since this metabolite has greater oestrogenic potency than either daidzein or O-dma and therefore excretor status could have physiological implications. Equol excretion in women has been associated with a hormonal profile of reduced risk for breast cancer (Duncan et al, 2000) . The relatively low prevalence for equol excretors observed in this study is comparable to rates seen in studies with isoflavones derived from soy, where 20-36% of subjects were reported to excrete equol (Kelly et al, 1993; Cassidy et al, 1994; Hutchins et al, 1995; Kirkman et al, 1995; Lampe et al, 1998; Duncan et al, 2000; Rowland et al, 2000) .
A distinctive feature of dietary isoflavonoids is their capacity to undergo structural transformations in the colon. This process is mediated by the resident microflora, which vary depending on the availability of nutrients that escape digestion in the upper gastrointestinal tract (Cummings & Macfarlane, 1991) . Fermentation of dietary fibre produces desirable short-chain fatty acids as a major end product, with a concomitant reduction in intraluminal pH (Cummings & Macfarlane, 1991; Rao et al, 1994) . In contrast, protein that escapes digestion can undergo putrefactive degradation by colonic bacteria forming less desirable products such as phenolic or indolic compounds and ammonia (Cummings & Macfarlane, 1991) . Dietary fibre appears to counteract this effect since concentrations of phenolic compounds and ammonia can be lowered by increased carbohydrate fermentation (Cummings & Macfarlane, 1991) . The reported effects of dietary protein and fibre on fermentative bacteria offer a possible physiological basis for the current findings in which there was no association between total isoflavonoid excretion and absolute intakes of protein or dietary fibre, but a highly significant inverse association with the relative intakes of these macronutrients, estimated by the protein to dietary fibre ratio. Fibre in this study was defined by the AOAC method (43.A14), which includes soluble and insoluble fibre, resistant starch and lignin.
Previous studies examining the interaction between macronutrient intake and isoflavonoid excretion provide some support for the proposal that intake of macronutrients could influence isoflavonoid excretion although there is no consensus about the nutrient of concern. Interventions with a soy protein beverage or textured soy protein reported that equol excretion was associated with significantly more carbohydrate and dietary fibre , or less fat and more carbohydrate (Rowland et al, 2000) , consumed in the habitual diet. Conversely, isoflavone excretion after a soy-rich meal was reduced by 13% when accompanied by a wheat fibre supplement (Tew et al, 1996) . However, two other studies found no changes in isoflavonoid excretion after treatment for 1 month with soy combined with a wheat fibre supplement (Lampe et al, 2001) or an increased intake of fat and protein . Discrepancies could arise from differences in design: two studies Rowland et al, 2000) focused on equol and did not evaluate total isoflavonoids, while in two other trials (Tew et al, 1996; Xu et al, 2000) , the experimental period of 1day may have been inadequate and data on the isoflavonoid metabolites were not reported. The present findings are consistent with a unifying hypothesis that isoflavonoid excretion is associated with the relative intakes of protein and dietary fibre; this could explain the apparent contradictions in previous studies in which possible interaction between these macronutrients was not explored.
Supplementation with purified isoflavones results in an increase in urinary isoflavonoid excretion and part of the individual variation in response could be explained by an interaction between intakes of protein and dietary fibre. Whether manipulation of these macronutrients could enhance efficacy of isoflavone supplements remains to be determined.
